{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-079816","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.950759+00:00","generated_at":"2026-05-17T11:52:26.736539+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio updates corporate presentation; posts preliminary cash of $8.8M as of June 30, 2025","bullets":["Preliminary cash of $8.8M as of June 30, 2025; audited FY2025 results expected later this quarter.","IBIO-610 (Activin E antibody) showed 8.9% body weight loss, 26% fat reduction, no lean mass loss in DIO mice.","IBIO-610 + semaglutide achieved 35.3% weight loss vs 27.8% alone; prevented weight regain after GLP-1 cessation.","IBIO-600 (anti-myostatin) half-life 40-52 days in NHPs; human estimate 57-147 days; CMC and GLP tox ongoing.","Partnered with AstralBio to develop amylin receptor agonist antibodies for obesity treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-079816","json":"https://secwatch.observer/filing/0001104659-25-079816.json","markdown":"https://secwatch.observer/filing/0001104659-25-079816.md","text":"https://secwatch.observer/filing/0001104659-25-079816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000110465925079816/0001104659-25-079816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000110465925079816/tm2523706d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:52:26.736539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}